We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Methods Evaluated to Detect Asymptomatic Visceral Leishmaniasis

By LabMedica International staff writers
Posted on 24 Jul 2019
Visceral leishmaniasis (VL) is caused by Leishmania infantum [synonymous L. More...
chagasi] in the New World or L. donovani in the Old World, VL can be classified as an anthroponotic or zoonotic disease because it is transmitted between humans and others mammals, such as dogs.
Visceral leishmaniasis in humans presents with fever, anemia, and splenomegaly and can be lethal if not treated. Nevertheless, the majority of L. infantum-infected individuals don’t manifest symptoms, and remain so provided they are not immunosuppressed. Direct and indirect methods are used for diagnosis of VL.

A team of scientists working with the Ribeirão Preto School of Medicine (Ribeirão Preto, Brazil) included in a study of patients with VL before and after treatment, who were hospitalized in the city of Teresina, and volunteers without any symptom of the disease residing in the same city. Sample collections were carried out between August and November 2017. Samples obtained from healthy volunteers residing in the city of Ribeirão Preto, were used as control of non-endemic area. The diagnosis of VL was confirmed by the positivity of amastigote forms in samples of bone marrow aspirate stained by Giemsa, and confirmed by cell culture in NNN medium.

Immunochromatographic tests (IC) were performed using Kalazar Detect Rapid, and the OnSite Leishmania IgG/IgM Combo test. An in-house enzyme-linked immunosorbent assay (ELISA) was performed and read on a Multiskan GO microplate spectrophotometer. DNA extraction was performed using 200 μL of total peripheral blood. IFN-γ-induced protein 10 (IP-10) and monokine induced by IFN-γ (MIG) were quantified in the study in 50 μL of plasma from whole blood soluble Leishmania antigen (SLA)-stimulated or non-SLA-stimulated using the BD Cytometric Bead Array Human Flex Set.

The scientists reported that Kalazar Detect and OnSite detected, respectively, 76% and 64% of patients presenting with active VL; 50% and 57% of patients remained positive in these tests, respectively, after treatment. Of the healthy participants in the study who were living in the endemic area, only 1.7% were positive with both of the IC tests. On the other hand, reactivity in ELISA tests revealed that 13% of these individuals presented asymptomatic infections; among VL patients, 84% presenting with active disease were reactive in ELISA and after treatment, 55.5% were seropositive. L. infantum DNA was present in the blood of 37.9% of infected individuals living in the endemic area, while IP-10 and MIG biomarkers were detected in 26.7% of them.

The authors concluded that the association of different techniques can detect asymptomatic infections, however, more investigation is necessary to develop ideal biomarkers that are simple to use in the clinic and in field studies in areas endemic for visceral leishmaniasis. The study was published on July 1, 2019, in the journal PLOS Neglected Tropical Diseases.

Related Links:
Ribeirão Preto School of Medicine


Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
New
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Whole-Cell Genomic Analysis Expands the Potential of Liquid Biopsy

Liquid biopsy has expanded access to tumor genomics, but most blood-based assays rely on short, degraded fragments of cell-free circulating tumor DNA (ctDNA). Isolating intact circulating tumor cells from... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.